Seasonal and pandemic influenza preparedness: Science and countermeasures

Journal of Infectious Diseases

Volumn 194, Issue SUPPL. 2, 2006, Pages

  Fauci, Anthony S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ALUMINUM POTASSIUM SULFATE; AMANTADINE; ANTIVIRUS AGENT; INFLUENZA H5N1 VACCINE; INFLUENZA VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; OSELTAMIVIR; PERAMIVIR; PROTEIN INHIBITOR; PROTEIN M2; RIMANTADINE; SIALIDASE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS VACCINE; ZANAMIVIR;

CLINICAL TRIAL; DRUG SCREENING; EPIDEMIOLOGICAL DATA; HEALTH CARE AVAILABILITY; HEALTH CARE PLANNING; HUMAN; INFLUENZA; INFLUENZA VACCINATION; MANAGEMENT; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASE; ORGANIZATION; PRIORITY JOURNAL; REVIEW; SEASONAL VARIATION; UNITED STATES; VIRUS STRAIN;

ACADEMIES AND INSTITUTES; ADULT; ANIMALS; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE OUTBREAKS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HEALTH PLANNING; HUMANS; INFANT; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; OSELTAMIVIR; SEASONS; UNITED STATES; VACCINATION; WORLD HEALTH;

EID: 33750365541     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/507550     Document Type: Review

References (11)

1. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289:179-86.
2. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA 2004; 292:1333-40.
3. World Health Organization. Confirmed human cases of avian influenza A (H5N1). Available at: http://www.who.int/csr/disease/avian_influenza/country/en/ . Accessed 30 August 2006.
4. US Department of Health and Human Services. HHS Pandemic Influenza Plan. Washington, DC: US Department of Health and Human Services, 2006. Available at: http://www.hhs.gov/pandemicflu/plan/. Accessed 9 August 2006.
5. US Homeland Security Council. National strategy for pandemic influenza implementation plan. Washington, DC: US Homeland Security Council, 2006.
6. Gerberding JL. Pandemic preparedness: pigs, poultry, and people versus plans, products, and practice. J Infect Dis 2006; 194(Suppl 2):S77-81 (in this supplement).
7. Ferguson NM, Cummings DAT, Cauchemz S, et al. Strategies for containing an emerging influenza pandemic in South East Asia. Nature 2005;437:209-14.
8. Longini IM Jr, Nizam A, Xu S, et al. Containing pandemic influenza at the source. Science 2005; 309:1083-7.
9. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006; 354:1343-51.
10. Bresson J-L, Perronne C, Launay O, et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006; 367:1336-8.
11. Atmar RL, Keitel WA, Patel SM, et al. Safety and immunogenicity of non-adjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis (in press).